Smart Cancer Nanotheranostics


QD Solar Chip 2(Nanowerk Spotlight) Cancer is one of the leading  causes of death in the world and remains a difficult disease to treat. Current  problems associated with conventional cancer chemotherapies include insolubility  of drugs in aqueous medium; delivery of sub-therapeutic doses to target cells;  lack of bioavailability; and most importantly, non-specific toxicity to normal  tissues. Recent contributions of nanotechnology research address possible  solutions to these conundrums. Nevertheless, challenges remain with respect to  delivery to specific sites, real time tracking of the delivery system, and  control over the release system after the drug has been transported to the  target site.

Nanomedical research on nanoparticles is exploring these issues  and has already been showing potential solutions for cancer diagnosis and  treatment. But a heterogeneous disease like cancer requires smart approaches  where therapeutic and diagnostic platforms are integrated into a theranostic  approach.

Theranostics – a combination of the words therapeutics and diagnostics – describes a treatment platform that combines a  diagnostic test with targeted therapy based on the test results, i.e. a step  towards personalized medicine. Making use of nanotechnology materials and  applications, theranostic nanomedicine can be understood as an integrated  nanotherapeutic system, which can diagnose, deliver targeted therapy and monitor  the response to therapy.

Theranostic nanomedicine has the potential for simultaneous and  real time monitoring of drug delivery, trafficking of drug and therapeutic  responses.

Our Smart Materials and Biodevice group at the Biosensors and Bioelectronics Centre, Linkoping University,  Sweden, has demonstrated for the first time a MRI-visual order-disorder micellar nanostructures for smart  cancer theranostics.

        drug release mechanism via functional outcome of pH response The  drug release mechanism via functional outcome of the pH response illustrated in  the schematic diagram. (Image: Smart Materials and Biodevice group, Linköping  University)   In the report, we fabricated a novel pH-triggered tumour  microenvironment sensitive order-disorder nanomicelle platform for smart  theranostic nanomedicine.             

The real-time monitoring of drug distribution will help  physicians to assess the type and dosage of drug for each patient and thus will  prevent overdose that could result in detrimental side-effects, or suboptimal  dose that could lead to tumour progression.

Additionally, the monitoring of normal healthy tissues by  differentiating with the MRI contrast will help balance the estimation of lethal  dose (for normal tissue) and pharmacologically active doses (for tumour). As a  result, this will help to minimize off-target effects and enhance effective  treatment.

In the present report, the concurrent therapy by doxorubicin and  imaging strategies by superparamagnetic iron oxide nanoparticles with our smart  architecture will provide every detail and thus can enable stratification of  patients into categorized responder (high/medium/low), and has the potential to  enhance the clinical outcome of therapy.

It shows, for the first time, concentration dependent  T2-weighted MRI contrast for a monolayer of clustered cancer cells. The pH  tunable order-disorder transition of the core-shell structure induces the  relative changes in MRI that will be sensitive to tumour microenvironment and  stages.

     MRI visual order-disorder nanostructure for cancer nanomedicine A  novel MRI visual order-disorder nanostructure for cancer nanomedicine explores  pH-trigger mechanism for theranostics of tumour hallmark functions. The pH  tunable order-disorder transition induces the relative changes in MRI contrast.  The outcome elucidates the potential of this material for smart cancer  theranostics by delivering non-invasive real-time diagnosis, targeted therapy  and monitoring the course and response of the action. (Image: Smart Materials  and Biodevice group, Linköping University)

Our findings illustrate the potential of these biocompatible  smart theranostic micellar nanostructures as a nontoxic, tumour-target specific,  tumour-microenvironment sensitive, pH-responsive drug delivery system with  provision for early stage tumour sensing, tracking and therapy for cells  over-expressed with folate receptors. The outcomes elucidate the potential of  smart cancer theranostic nanomedicine in non-invasive real-time diagnosis,  targeted therapy and monitoring of the course and response of the action before,  during and after treatment regimen.

By Hirak K Patra, Nisar Ul Khali, Thobias Romu, Emilia  Wiechec, Magnus Borga, Anthony PF Turner and Ashutosh Tiwari, Biosensors and Bioelectronics Centre,  Linköping University, Sweden

Read more: http://www.nanowerk.com/spotlight/spotid=33186.php#ixzz2kTi8huZB

QMC & DOE collaborate on tetrapod quantum dot research


Mar 28, 2013    

QDOTS imagesCAKXSY1K 8Quantum Materials Corporation has recently developed and delivered customized tetrapod QD samples for applications being developed by the US Department of Energy National Lab researchers.

As one of the largest sponsors of U.S. technical and military research, the DOE helps to move innovative technologies into the commercial marketplace, creating new jobs and future industries.

Quantum Materials Corporation (QMC) has also agreed to supply customized tetrapod quantum dots to a U.S. government defense related agency in support of a nano-biological project.

More than 110 science-related Nobel Prizes have been awarded to DOE-associated researchers.

Department of Energy National (DOE) Labs, Energy Innovation Hubs and Technology Centers are developing quantum dot and other nanoscale applications.

Relevant applications include solar photovoltaics, batteries, biofuels, physics and biological sciences.

One institute working on the project is Los Alamos National Lab (LANL), which is exploring quantum dot-fluorescent proteins (QD-FP) in devices. They use pH-sensitive fluorescent protein acceptors to produce long-lived sensors for biological imaging. LANL’s use of quantum dots for precise cellular imaging produces valuable data for the hopeful cure or treatment of many diseases and conditions.

QMC believes its technology meets three NNI National Signature Initiatives objectives. These are new advanced materials (tetrapod quantum dots), mass production (continuous flow process) and nano-manufacturing (roll-to-roll printing).

Stephen Squires, QMC CEO commented, “The many DOE National Labs are in the forefront of quantum dot research and we welcome the opportunity to collaborate with them. QMC has enabling technologies to help fulfill NNI National Signature Initiatives years ahead of forecasts, advancing the nation’s research rapidly while perhaps saving the U.S. Government millions that can be redirected to application development.”

QMC currently offers high-brightness cadmium-based and ecological cadmium-free non-heavy metal tetrapod QD and can synthesize many Group II-VI inorganic mono or hybrid tetrapod quantum dots.

The firm intends to build out its quantum dot production facilities in the U.S. with full commercial production expected in the fourth quarter of 2013.

 

QDOTS imagesCAKXSY1K 8